Clinical Trial

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2026-09-01 -> 2025-12-14 2026-07-23
notable Primary completion pushed: 2026-03 -> 2026-09-01 2026-04-22
minor Completion pushed: 2028-03 -> 2028-09 2026-04-22
Trial Details
NCT Number NCT04114981
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Malignant Neoplasm in the Brain
Enrollment 242 participants
Start Date 2019-11-19
Primary Completion 2025-12-14 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-22